The Lymphoma Hub was pleased to speak with Christopher P. Fox, University of Nottingham, UK. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?

In this interview, Fox discusses the 3-year follow-up results from the global, randomized, phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) (n = 183) vs rituximab (R)-GemOx (n = 91) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), recently published in Blood Advances. He also explores outcomes across clinically relevant subgroups.

Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Peter Borchmann, University Hospital Cologne, Cologne, DE. We asked, How might key findings from the HD21 trial influence 1L treatment of advanced stage cHL?

In this interview, Borchmann discusses results from the randomized, multicenter, phase III HD21 trial (NCT02661503), which evaluated positron emission tomography-guided brentuximab vedotin + etoposide + cyclophosphamide + doxorubicin + dacarbazine + dexamethasone (BrECADD; n = 751) vs bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisolone (eBEACOPP; n = 749) in adults aged ≤60 years with advanced-stage classical Hodgkin lymphoma.

Intended for healthcare professionals. This educational resource is independently supported by Takeda. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak to Nirav Shah, Medical College of Wisconsin, Milwaukee, US. We asked, What is the current clinical evidence for tandem chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?

This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Peter Borchmann, University Hospital Cologne, DE. We asked, What is the rationale for the development of tandem chimeric antigen receptor (CAR) T-cell therapies?

Intended for healthcare professionals. This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, led a case-based presentation and panel discussion featuring Susan O’Brien, Farrukh Awan, and Gilles Salles on optimizing chronic lymphocytic leukemia management in a changing landscape.

This educational activity is independently supported by Eli Lilly and Company. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas Southwestern Medical Center, Dallas, US, delivered a presentation on BTK inhibitors in practice: Treatment selection and emerging clinical evidence.

This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Susan O’Brien, University of California Irvine, US, delivered a presentation on BTK inhibitors in chronic lymphocytic leukemia: Mechanisms, clinical considerations, and unmet needs.

This educational resource is independently supported by Eli Lilly and Company. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.

The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)?

This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Hosted on Acast. See acast.com/privacy for more information.